That brings its total raised to $2.62 million since 2017.
Twenty-eight investors contributed to the round, which is capped at around $4 million, with roughly $1.5 million remaining to be sold.
The filing did not indicate the company’s use of proceeds.
Launched in 2016, URO-1 is an emerging medical device company developing disposable products for office procedures in urogynecology and urology.
Its inaugural product, the Repris Bladder Injection System, has recently been cleared to market by the US FDA. It is specifically designed to help reduce complications following onabotulinumtoxinA treatment for overactive bladder (OAB) in women. Repris features the unique Re4m memory cannula platform and the Rely “no look” self-metering syringe.
Additional products are currently in late-stage development.
It is led by Ted Belleza, a California-based entrepreneur and business development executive with three decades of experience at several successful medical device companies. In late 2010 he co-founded EndoSee, maker of a hand-held disposable office hysteroscope — a thin, lighted tube that is inserted into the vagina to examine the cervix and inside of the uterus. The company was acquired by Cooper Surgical in 2014.
Belleza came out of an 18-month retirement in 2017 to lead URO-1.